Additional Relevant Details TRACON Pharmaceuticals  announced that it had begun Phase 2 clinical trials of the combined treatment of patients with glioblastoma with TRC102 ("clinical-state small molecule inhibitor of the DNA base excision repair pathway”) and Temodar (temozolomide).  Sponsored by the National Cancer Institute, this study aims to demonstrate TRC102 as an inhibitor to BER pathway of chemotherapy resistance.  The estimated primary completion date for this study is February 2017 (ClinicalTrials.gov).